ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Markers Of Insulin Resistance and Their Clinical Implications In Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Determinants of Metabolic Dysfunction-Associated Steatotic Liver Diseases in Patients with Type 2 Diabetes Mellitus.Journal of clinical medicine · 2026Article
- Insulin resistance drives GGT elevation in MASLD with diabetes: evidence from clinical cohorts, mendelian randomization and functional genomics.Nutrition & diabetes · 2026Article
- Non-linear associations of the triglyceride-glucose index with thyroid function in a large Chinese population: a cross-sectional study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insulin resistance, type 2 diabetes (T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD) are pathogenically interconnected conditions, being part of a dysfunctional metabolic continuum that explains the high frequency of MASLD in patients with T2D. Purpose: The present study evaluated the prevalence of MASLD in patients with T2D and identified key risk factors. We correlated MASLD with insulin resistance and other cardiovascular risk factors to determine cutoff values for increased hepatic steatosis risk. Methods: We cross-sectionally evaluated 256 T2D patients (median age 63.5 years, 54.3% female) admitted to a regional diabetes center. MASLD diagnosis was based on FibroScan Echosens and standard clinical criteria. We recorded comorbidities and metabolic parameters, and calculated insulin resistance indexes, including TyG and METS-IR scores. We correlated MASLD with insulin resistance and other cardiovascular risk factors to determine cutoff values for increased hepatic steatosis risk. Results: MASLD was present in 87.5% (95% CI: 76.4-99.7) of patients. TyG index and METS-IR showed statistically significant associations with MASLD presence, and ROC analysis indicated moderate discrimination (AUC values 0.80-0.86). ROC analysis identified HbA1c >7.2% as a discriminative threshold for MASLD, but predictive accuracy was modest (AUC 0.696). Conclusion: In patients with T2D, suboptimal glycemic control and insulin resistance are associated with MASLD and fibrosis. Insulin resistance markers, TyG and METS-IR, were significantly associated with MASLD and showed moderate discriminative capacity in ROC analysis, suggesting potential value for screening. Incorporating these indices into routine assessment may improve identification of high-risk patients and guide timely interventions to prevent disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.